Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and
Cathal Friel, Executive Chairman of Open Orphan, commented: We are very happy to be assisting in the battle against Covid-19 and are delighted to be working with Nearmedic International Ltd.
Leeds, UK, April 17, 2020 – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the key findings of a planned interim analysis
Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK
Open Orphan , the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine
Cathal Friel, Executive Chairman of Open Orphan, said: As I said in our RNS announcement of the 20th of January, I am hugely excited by the combination of Open Orphan
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, confirms that as previously announced it is currently undertaking meetings with investors
Open Orphan Plc announced the completion of its acquisition of UK-based hVivo Plc on Monday, 20th January 2020.
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext
On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and
The Boards of Open Orphan and hVIVO have reached an agreement on the terms of a recommended Offer to be made by Open Orphan for the entire issued and to
